We are live on ! Find out more
KTTAW icon

Pasithea Therapeutics Warrants
KTTAW

6 hedge funds and large institutions have $12.7K invested in Pasithea Therapeutics Warrants in 2024 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

64.03% more ownership

Funds ownership: 3.42% → 67.45% (+64%)

46% more capital invested

Capital invested by funds: $8.68K → $12.7K (+$4K)

0% more funds holding

Funds holding: 6 → 6 (0)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
6
Holders Change
–
Holders Change %
0%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
WAM
Warberg Asset Management
Illinois
-$157
Name Holding Trade Value Shares
Change 		Change in
Stake
KC
1
Kepos Capital
New York
$7K – – –
WAM
2
Warberg Asset Management
Illinois
$4.26K -$157 -11,184 -4%
AC
3
Armistice Capital
New York
$995 – – –
MG
4
Marex Group
$275 – – –
Citadel Advisors
5
Citadel Advisors
Florida
$144 – -15 -0.1%

KTTAW Hedge Fund Activity: Q2 2024 in Review

6 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics Warrants (KTTAW) for Q2 2024, worth a combined $12.7K — up 46% from $8.68K a quarter earlier.

Fund positioning in KTTAW was balanced in Q2 2024: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 2 trimmed.

The largest seller was Warberg Asset Management, cutting an estimated $157.

  • 6 institutional investors held Pasithea Therapeutics Warrants (KTTAW) as of Q2 2024, unchanged from Q1 2024.
  • Funds reported $12.7K of Pasithea Therapeutics Warrants stock for Q2 2024, up 46% quarter-over-quarter.
  • 0 funds opened new Pasithea Therapeutics Warrants positions in Q2 2024 and 0 closed out.
  • The largest Pasithea Therapeutics Warrants seller in Q2 2024 was Warberg Asset Management, an estimated $157 sold.

Based on aggregated 13F filings for Q2 2024.